Europe Cell Line Development Market Forecasts to 2024: Projecting a CAGR of 12.5%

Growing disease burden across the globe is the key factor that will drive cell line development market growth. Rising demand for vaccines and monoclonal antibodies in treatment of cancer, autoimmune diseases and anti-inflammatory disease will fuel demand for cell line cultures. Developments in biotechnology industry, increasing healthcare expenditure coupled with growing adoption of technologically advanced products should accelerate the cell line development industry growth.According to the Graphical Research new growth forecast report titled "Europe Cell Line Development Market analysis based on Product, Source, Cell Line, Application, Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2018 - 2024", estimated to exceed USD 2.1 billion by 2024. Key industry players operating in Europe cell line development market are Selexis, Sartorius, Lonza Group, Samsung Biologics, WuXi AppTec, GE Healthcare, Thermo Fisher Scientific, The European Collection of Cell Cultures, Sigma-Aldrich (Merck), GVK BIO, and Progenitor Cell Therapy. Industry players are adopting strategies including merger, acquisition and strategic collaboration and partnership to expand their product portfolio as well as augment consumer base in the industry.

Request for a sample of this report @ https://www.graphicalresearch.com/request/1066/sample

Technological advancements in cell line development products is another major contributor for cell line development business growth. Availability of automated screening methods, enriched medias, disposable equipment and improved expression systems for enhancing cell line development practices will foster market growth. However, stringent regulatory constraints may hamper the cell line development industry growth over the forecast timeframe.

Reagents and media product segment accounted for largest market share of 53.6% in 2017 and is projected to show robust growth throughout the analysis period. Reagents and media form major component of cell culture procedures. Increasing usage of reagents and media in drug discovery, tissue engineering and other research applications will accelerate the segmental growth over the analysis period.

Mammalian cell cultures segment was valued at USD 650.8 million in 2017 and is estimated to show similar growth during the forecast period. The growth is attributable to increasing adoption of mammalian cell cultures for production of complex biotherapeutic proteins. Mammalian cell cultures are widely used in vaccine production for treatment of mumps, rubella and other diseases. Increasing acceptance of mammalian cell source to produce monoclonal antibodies will further boost the segmental growth.

Recombinant cell line type segment is anticipated to grow at 12.5% CAGR during the forthcoming years. Advent of rDNA technology has drastically increased the demand for recombinant cell lines. Wide adoption of rDNA technology in production of enzymes, synthetic hormones, immunobiologics and other anti-cancer drugs will foster growth of recombinant cell line type segment. Increasing demand for monoclonal antibodies in improving quality of life in patients suffering from cancer, anti-inflammatory disorders and autoimmune diseases will positively impact the segmental growth.

Germany cell line development market will grow considerably during the forecast period owing to increasing disease burden in the region. Growing adoption of vaccines and monoclonal antibodies will foster cell line development industry growth. Increasing investments in R&D activities will fuel the demand for cell cultures thereby driving business growth. Developments in biotechnology industry will further augment Germany cell line development market growth.

Europe Cell Line Development Market Size By Product (Reagents & Media, Equipment {Incubator, Centrifuge, Bioreactor, Storage Equipment, Microscope}, Accessories & Consumables), By Source (Mammalian, Non-Mammalian {Insects, Amphibians}), By Cell Line (Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line), By Application (Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research), Industry Analysis Report, Regional Outlook (Germany, UK, France, Spain, Italy, Russia, Ukraine, Poland, Switzerland, Belgium, Greece, Czech Republic, Netherlands, Sweden), Application Potential, Competitive Market Share & Forecast, 2018 - 2024.

Make an Inquiry for purchasing this Report @ https://www.graphicalresearch.com/request/1066/inquiry-before-buying

Report Content

Chapter 1. Methodology

1.1. Methodology

1.2. Market definitions

1.3. Forecast parameters

1.4. Data sources

1.4.1. Secondary

1.4.1.1. Paid sources

1.4.1.2. Unpaid sources

1.4.2. Primary

Chapter 2. Executive Summary

2.1. Europe cell line development market industry 3600 synopsis, 2013 – 2024

Chapter 3. Europe Cell Line Development Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2013 – 2024

3.3. Industry impact forces

3.3.1. Growth drivers

3.3.1.1. Growing vaccine production

3.3.1.2. Increasing number of cancer incidences

3.3.1.3. Extended applications of biotechnology sector

3.3.1.4. Patent expiration of blockbuster biologics leading to innovations in the field

3.3.1.5. Escalating demand for monoclonal antibodies in Europe

3.3.1.6. Technological advancements in cell line development

3.3.2. Industry pitfalls & challenges

3.3.2.1. Growing concerns related to stem cell research

3.4. Growth potential analysis

3.4.1. By product

3.4.2. By source

3.4.3. By cell-line type

3.4.4. By application

3.5. Competitive landscape, 2017

3.5.1. Strategy dashboard

3.6. Porter’s analysis

3.7. PESTEL analysis

Europe cell line development market will show robust growth over the coming years owing to increasing developments in biotechnology industry. Growing adoption of cell line development technologies for production of vaccines and monoclonal antibodies will foster industry growth. Furthermore, technological advancements will serve to be major contributor for industry growth. For instance, in Feb 2016, Irvine Scientific launched BalanCD CHO Feed 4, a chemically defined, animal component-free powder feed to facilitate large scale bioproduction of high performing CHO cells.

Graphical Research is a business research firm that provides industry insights, market forecast and strategic inputs through granular research reports and advisory services.